Please assess the completion status of the following clinical trial:

Trial Title: Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has a clinical diagnosis of RVO in the study eye~* Has a CST of ≥ 300 µm in the study eye~* Has an ETDRS BCVA score of ≥ 20 letters read and ≤ 70 letters read in the study eye;~* Is naïve to local pharmacologic treatment for RVO in the study eye;~Exclusion Criteria:~* Any active ocular disease or infection in the study eye other than RVO~* History of glaucoma, intraocular pressure \> 21 mmHg or ocular hypertension requiring more than one medication~* Any uncontrolled systemic disease that, in the opinion of the Investigator, would preclude participation in the study~* Any evidence of neovascularization in the study eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): IVT aflibercept (2 mg/0.05 mL) + CLS-TA (4 mg/100 µL) SC injections
- Control (Type: ACTIVE_COMPARATOR): IVT aflibercept (2 mg/0.05 mL) + sham SC procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).